Opiant Pharmaceuticals (OPNT) Misses Q1 EPS by 22c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update
May 12, 2020 4:05 PM EDTSANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2020, and provided a corporate update. Recent highlights include:
Strong financial position: - Q1 2020 revenues of $4.3 million driven by NARCAN® Nasal Spray (NARCAN®) royalties of $4.2 million, an increase of 12 percent year-over-year- Projected royalties for the full-year 2020 of approximately $26.2 million, reiterated based on Emergent BioSolutions Inc. (EBS) revenue guidance for NARCAN®- Cash... More